Treat-And-extend bevacizumab for neovascular age-related macular degeneration: The importance of baseline characteristics

Retina

Volumn 34, Issue 5, 2014, Pages 846-852

  Rush, Ryan B ^a,b   Simunovic, Matthew P ^c,d   Vandiver, Lorelei ^b   Aragon, Antonio V ^a,b   Ysasaga, Jason E ^a,b  

^a Southwest Retina Specialists   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c SYDNEY EYE HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Age related macular degeneration; Bevacizumab; Posterior vitreous detachment; Treat And extend

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; COLORING AGENT; INDOCYANINE GREEN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; CENTRAL MACULAR THICKNESS; DRUG EFFICACY; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; VISUAL ACUITY CHART; VITREOUS BODY DETACHMENT; AGE; ANTAGONISTS AND INHIBITORS; DIAGNOSTIC USE; FEMALE; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; MALE; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PHYSIOLOGY; RETINA; RISK FACTOR; TREATMENT OUTCOME; VITREOUS DETACHMENT; WET MACULAR DEGENERATION;

AGE FACTORS; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORING AGENTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOCYANINE GREEN; INTRAVITREAL INJECTIONS; MALE; RETINA; RETROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS DETACHMENT; WET MACULAR DEGENERATION;

EID: 84899954770     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000033     Document Type: Article

References (19)

1. Bressler NM, Bressler SB, Congdon NG, et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 2003;121:1621-1624.
2. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81:154-162.
3. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25: 111-118.
4. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
5. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
6. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119: 1388-1398.
7. Jumper JM, Mittra RA; American Society of Retina Specialists. Preferences and trends survey, 2012. Available at: www. asrs. org/content/documents/2012- Asrs-patsurvey-results. pdf. Accessed April 1, 2013.
8. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010;117:2134-2140.
9. Oubraham H, Cohen SY, Samimi S, et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 2011;31:26-30.
10. Shienbaum G, Gupta OP, Fecarotta C, et al. Bevacizumab for neovascular age-related macular degeneration using a treatand- extend regimen: clinical and economic impact. Am J Ophthalmol 2012;153:468-473.
11. AcaStat, 8. 1. 4 ed. Leesburg, VA; 2011.
12. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
13. Engelbert M, Zweifel SA, Freund KB. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina 2009;29:1424-1431.
14. Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120:122-129.
15. Goldenberg DT, Trese MT. Pharmacologic vitreodynamics and molecular flux. Dev Ophthalmol 2009;44:31-36.
16. Quiram PA, Leverenz VR, Baker RM, et al. Microplasmininduced posterior vitreous detachment affects vitreous oxygen levels. Retina 2007;27:1090-1096.
17. Goldenberg DT, Giblin FJ, Cheng M, et al. Posterior vitreous detachment with microplasmin alters the retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes. Retina 2011; 31:393-400.
18. Krohne TU, Eter N, Holz FG, et al. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146:508-512.
19. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114:855-859.